90%Confidence
0Views
FDASource
2026-03-03Date
Summary
Another Fresenius Kabi Compounding recall for ketamine HCl sterility issues suggests systemic quality control problems. This could affect surgical and pain management protocols relying on compounded anesthetics.
Actionable: Immediately quarantine all Fresenius Kabi Compounding ketamine products and seek alternative suppliers.
AI Confidence: 90%
Data Points
firmFresenius Kabi Compounding, LLC
classificationClass II
statusOngoing
distributionUS Nationwide.
productketamine HCl, 1,000 mg, 1,000 mg per 100 mL (10 mg per mL) in Sodium Chloride Injection, Fagron Sterile Services, 20 Dan Road, Canton, MA 02021, NDC 7
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now